» Articles » PMID: 34589433

Neoadjuvant Chemotherapy Followed by Surgery Versus Abdominal Radical Hysterectomy Alone for Oncological Outcomes of Stage IB3 Cervical Cancer-A Propensity Score Matching Analysis

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Sep 30
PMID 34589433
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To compare the 5-year overall survival (OS) and disease-free survival (DFS) of patients with cervical cancer who received neoadjuvant chemotherapy followed by surgery (NACT) with those who received abdominal radical hysterectomy alone (ARH).

Methods: We retrospectively compared the oncological outcomes of 1410 patients with stage IB3 cervical cancer who received NACT (n=583) or ARH (n=827). The patients in the NACT group were divided into an NACT-sensitive group and an NACT-insensitive group according to their response to chemotherapy.

Results: The 5-year oncological outcomes were significantly better in the NACT group than in the ARH group (OS: 96.2% 91.2%, respectively, =0.002; DFS: 92.2% 87.5%, respectively, =0.016). Cox multivariate analysis suggested that NACT was independently associated with a better 5-year OS (HR=0.496; 95% CI, 0.281-0.875; =0.015), but it was not an independent factor for 5-year DFS (HR=0.760; 95% CI, 0.505-1.145; =0.189). After matching, the 5-year oncological outcomes of the NACT group were better than those of the ARH group. Cox multivariate analysis suggested that NACT was still an independent protective factor for 5-year OS (HR=0.503; 95% CI, 0.275-0.918; =0.025). The proportion of patients in the NACT group who received postoperative radiotherapy was significantly lower than that in the ARH group (<0.001). Compared to the ARH group, the NACT-sensitive group had similar results as the NACT group. The NACT-insensitive group and the ARH group had similar 5-year oncological outcomes and proportions of patients receiving postoperative radiotherapy.

Conclusion: Among patients with stage IB3 cervical cancer, NACT improved 5-year OS and was associated with a reduction in the proportion of patients receiving postoperative radiotherapy. These findings suggest that patients with stage IB3 cervical cancer, especially those who are sensitive to chemotherapy, might consider NACT followed by surgery.

Citing Articles

Meta-analysis of the efficacy and safety of Xihuang Pills/capsules in adjuvant treatment of uterine cervical neoplasms.

Xu H, Tian G, Wu C, Sun X, Li K Medicine (Baltimore). 2023; 102(34):e34846.

PMID: 37653807 PMC: 10470801. DOI: 10.1097/MD.0000000000034846.


Cervical cancer in Cape Verde: reappraisal upon referral to a tertiary cancer centre.

Vilares A, Ciabattoni R, Cunha T, Felix A Ecancermedicalscience. 2023; 16:1471.

PMID: 36819824 PMC: 9934889. DOI: 10.3332/ecancer.2022.1471.


Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial.

Hu Y, Han Y, Shen Y, Chen J, Chen Y, Chen Y BMC Cancer. 2022; 22(1):1270.

PMID: 36471257 PMC: 9724322. DOI: 10.1186/s12885-022-10355-3.

References
1.
Cai H, Chen H, Yin H . Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer. J Obstet Gynaecol Res. 2006; 32(3):315-23. DOI: 10.1111/j.1447-0756.2006.00404.x. View

2.
Yang Z, Chen D, Zhang J, Yao D, Gao K, Wang H . The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: A randomized multicenter study. Gynecol Oncol. 2015; 141(2):231-239. DOI: 10.1016/j.ygyno.2015.06.027. View

3.
Li W, Liu P, Zhao W, Yin Z, Lin Z, Bin X . Effects of preoperative radiotherapy or chemoradiotherapy on postoperative pathological outcome of cervical cancer--from the large database of 46,313 cases of cervical cancer in China. Eur J Surg Oncol. 2019; 46(1):148-154. DOI: 10.1016/j.ejso.2019.09.188. View

4.
Eddy G, Bundy B, Creasman W, Spirtos N, Mannel R, Hannigan E . Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007; 106(2):362-9. DOI: 10.1016/j.ygyno.2007.04.007. View

5.
Katsumata N, Yoshikawa H, Kobayashi H, Saito T, Kuzuya K, Nakanishi T . Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer. 2013; 108(10):1957-63. PMC: 3671094. DOI: 10.1038/bjc.2013.179. View